Revolutionary Findings in HER2-Positive Advanced Breast Cancer
On a significant morning during a leading breast cancer symposium, RemeGen Co. Ltd. (9995.HK, 688331.SH) unveiled the important results of their phase III study focusing on Disitamab Vedotin (DV), a treatment for patients grappling with HER2-positive advanced breast cancer along with liver metastasis. This presentation stood out at one of the largest annual meetings dedicated to breast cancer research, garnering the attention of experts throughout the globe.
The Challenge of Liver Metastasis in Breast Cancer
A striking statistic reveals that approximately 45% of patients diagnosed with HER2-positive advanced breast cancer face liver metastasis—a condition known to carry a very poor prognosis. This challenging subset of patients has a survival rate of merely 8% to 12% across five years, and until now, satisfactory treatment options have been quite limited.
Insight into the Study's Design and Results
The study, a multicenter phase III endeavor, was designed to compare the efficacy and safety of DV against Lapatinib combined with Capecitabine among these patients. Specifically, 104 individuals participated in the study, with 53 receiving DV and 50 undergoing treatment with Lapatinib and Capecitabine. Importantly, all participants had already undergone treatments with Trastuzumab and Taxanes, highlighting the difficulty of treating such cases.
Progression-Free Survival Metrics
Upon reviewing the data as of the designated cutoff date, it became clear that DV significantly improved progression-free survival (PFS) compared to Lapatinib and Capecitabine. The median PFS reported was 9.9 months for those treated with DV versus just 4.9 months for the alternative treatment, presenting a hazard ratio [HR] of 0.56, which is a favorable outcome that encourages further investigation. Additionally, the overall survival (OS) data indicated a positive trend favoring DV, although it is still considered preliminary.
Safety Profile and Final Observations
Participants experienced a safety profile for DV that was aligned with previous uses, with no alarming new safety signals identified. Professor Jiayu Wang, who led the study presentation, remarked on the groundbreaking nature of the findings, confirming that this was indeed the first confirmatory phase III study showing promising efficacy of an HER2-targeting antibody-drug conjugate (ADC) specifically for patients suffering from HER2-positive advanced liver metastasis.
Looking Forward: Regulatory Pathway
As a noteworthy step forward, the Biologics License Application (BLA) for DV has recently been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration in China. This acceptance includes priority review status, awarded due to the breakthrough designation received earlier. Given how crucial these advancements are, they represent a significant potential new treatment avenue for patients who have been pre-treated with Trastuzumab and Taxanes.
Frequently Asked Questions
What is Disitamab Vedotin used for?
Disitamab Vedotin is designed to treat patients with HER2-positive advanced breast cancer, particularly those with liver metastasis.
Who led the presentation at the SABCS?
Professor Jiayu Wang from the Cancer Hospital, Chinese Academy of Medical Sciences presented the results of the study.
What were the major findings of the study?
The study found that DV significantly improved progression-free survival compared to the standard treatment of Lapatinib with Capecitabine.
What does the BLA acceptance indicate?
The acceptance of the Biologics License Application suggests that DV might soon become an approved treatment for patients who have limited options available.
Is there ongoing research related to this treatment?
Yes, ongoing research aims to further investigate the efficacy and safety of Disitamab Vedotin in larger patient populations.
